Aldeyra Therapeutics (ALDX) News Today $6.67 +0.41 (+6.55%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$6.61 -0.06 (-0.88%) As of 03/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Aldeyra options imply 29.5% move in share price post-earningsMarch 28 at 8:32 PM | markets.businessinsider.comRaymond James Financial Inc. Invests $3.63 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Raymond James Financial Inc. acquired a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 727,118 shares of the biotechnology compaMarch 28 at 3:21 AM | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Share Price Passes Above 50 Day Moving Average - Should You Sell?March 26, 2025 | americanbankingnews.comAldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Above 50-Day Moving Average - Here's WhyAldeyra Therapeutics (NASDAQ:ALDX) Share Price Passes Above 50-Day Moving Average - Here's What HappenedMarch 26, 2025 | marketbeat.comAldeyra options imply 30.8% move in share price post-earningsMarch 21, 2025 | markets.businessinsider.com151,280 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Acquired by Kennondale Capital Management LLCKennondale Capital Management LLC acquired a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 151,280 shares of the bioteMarch 19, 2025 | marketbeat.comAldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare ConferenceMarch 10, 2025 | finance.yahoo.comAldeyra Therapeutics (ALDX) Receives a Buy from JonesTradingMarch 7, 2025 | markets.businessinsider.comQ1 Earnings Forecast for ALDX Issued By HC WainwrightAldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Aldeyra Therapeutics in a research note issued on Monday, March 3rd. HC Wainwright analyst M. Caufield anticipates that the biotechnology company will postMarch 7, 2025 | marketbeat.comAldeyra Therapeutics Is Severely Undervalued Before PDUFAMarch 5, 2025 | seekingalpha.comAldeyra Therapeutics (NASDAQ:ALDX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Monday.March 3, 2025 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Posts Earnings Results, Misses Estimates By $0.30 EPSAldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) announced its quarterly earnings results on Friday. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.30).March 1, 2025 | marketbeat.comAldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on ThursdayAldeyra Therapeutics (NASDAQ:ALDX) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comAlphaCentric Advisors LLC Takes $234,000 Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)AlphaCentric Advisors LLC bought a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 46,913 shares of the biotechnology comFebruary 17, 2025 | marketbeat.comALDX stock touches 52-week high at $6.6 amid robust annual gainsFebruary 14, 2025 | msn.comAldeyra Therapeutics, Inc. (ALDX) Notice: Grabar Law Office Is Investigating Claims for Long-Term ShareholdersFebruary 5, 2025 | markets.businessinsider.comAldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | finance.yahoo.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 8.2% in JanuaryAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 3,840,000 shares, an increase of 8.2% from the December 31st total of 3,550,000 shares. Based on an average daily volume of 463,300 shares, the short-interest ratio is currently 8.3 days.February 2, 2025 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Stock Price Crosses Below 200-Day Moving Average - Here's WhyAldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 200-Day Moving Average - Should You Sell?January 28, 2025 | marketbeat.comIs Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?January 20, 2025 | insidermonkey.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest UpdateAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,840,000 shares, an increase of 8.2% from the December 15th total of 3,550,000 shares. Based on an average trading volume of 463,300 shares, the days-to-cover ratio is currently 8.3 days.January 19, 2025 | marketbeat.comInternational Assets Investment Management LLC Trims Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)International Assets Investment Management LLC decreased its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 79.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,750 shares of the bJanuary 13, 2025 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Shares Pass Below 50 Day Moving Average - Here's What HappenedAldeyra Therapeutics (NASDAQ:ALDX) Shares Pass Below 50 Day Moving Average - Time to Sell?December 28, 2024 | marketbeat.comAldeyra Therapeutics: Key Inflection Point AheadDecember 26, 2024 | seekingalpha.comVerition Fund Management LLC Sells 186,297 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Verition Fund Management LLC cut its stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 84.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,530 shares of the biotechnology compDecember 17, 2024 | marketbeat.comShort Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Drops By 12.3%Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 3,410,000 shares, a decline of 12.3% from the November 15th total of 3,890,000 shares. Based on an average daily volume of 476,600 shares, the short-interest ratio is currently 7.2 days.December 15, 2024 | marketbeat.comPositive Outlook for Aldeyra Therapeutics: Buy Rating Backed by Promising Reproxalap Prospects and Strategic Partnership with AbbVieDecember 10, 2024 | markets.businessinsider.comJacobs Levy Equity Management Inc. Grows Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Jacobs Levy Equity Management Inc. boosted its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 163.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 476,949 shares of the biotechnologyDecember 8, 2024 | marketbeat.comAldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare ConferenceDecember 3, 2024 | finance.yahoo.comEagle Asset Management Inc. Sells 132,053 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Eagle Asset Management Inc. cut its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 15.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 709,518 shares of the biotechnology company'sNovember 25, 2024 | marketbeat.comAldeyra Therapeutics Shares Up, FDA to Review New Drug ApplicationNovember 19, 2024 | marketwatch.comAldeyra Therapeutics Says FDA Accepts NDA For Reproxalap In Dry Eye DiseaseNovember 19, 2024 | markets.businessinsider.comAldeyra says FDA accepts reproxalap NDA, AbbVie deal expanded to $100MNovember 19, 2024 | markets.businessinsider.comAldeyra announces FDA acceptance of resubmitted reproxalap applicationNovember 19, 2024 | msn.comResearch Analysts Set Expectations for ALDX FY2024 EarningsAldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2024 earnings estimates for Aldeyra Therapeutics in a report issued on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will post eaNovember 18, 2024 | marketbeat.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Significant Increase in Short InterestAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,670,000 shares, an increase of 7.9% from the October 15th total of 3,400,000 shares. Currently, 6.4% of the shares of the company are sold short. Based on an average trading volume of 443,400 shares, the days-to-cover ratio is presently 8.3 days.November 17, 2024 | marketbeat.comWhat is Leerink Partnrs' Estimate for ALDX FY2028 Earnings?Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Research analysts at Leerink Partnrs reduced their FY2028 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a report released on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now expects that the biotechNovember 15, 2024 | marketbeat.comAldeyra Therapeutics to Participate in the Jefferies London Healthcare ConferenceNovember 15, 2024 | finance.yahoo.comAldeyra Therapeutics’ Reproxalap: Promising Pipeline and Strategic Partnerships Justify Buy RatingNovember 9, 2024 | markets.businessinsider.comAldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 MeetingOctober 31, 2024 | finance.yahoo.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Purchased by International Assets Investment Management LLCInternational Assets Investment Management LLC grew its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 397.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 287,287 shares of thOctober 30, 2024 | marketbeat.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Large Increase in Short InterestAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 3,400,000 shares, a growth of 13.3% from the September 30th total of 3,000,000 shares. Based on an average daily volume of 532,600 shares, the short-interest ratio is presently 6.4 days. Approximately 5.9% of the company's shares are short sold.October 29, 2024 | marketbeat.comDimensional Fund Advisors LP Sells 210,153 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Dimensional Fund Advisors LP lowered its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 23.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 672,057 shares of the biotechnology company's stock after seOctober 12, 2024 | marketbeat.comAldeyra Therapeutics extends loan agreement termsOctober 4, 2024 | investing.comRenaissance Technologies LLC Sells 224,390 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Renaissance Technologies LLC lowered its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 30.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 503,300 shares of the biotechnology company's sOctober 4, 2024 | marketbeat.comLexington biotech resubmits dry eye drug for FDA approval a year after rejectionOctober 3, 2024 | bizjournals.comAldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease TreatmentOctober 3, 2024 | marketwatch.comAldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseOctober 3, 2024 | stockhouse.comAldeyra Therapeutics Reports Resubmission Of NDA For Topical Ocular ReproxalapOctober 3, 2024 | markets.businessinsider.comPerceptive Advisors LLC Acquires 682,265 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Perceptive Advisors LLC increased its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 7.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,275,851 shares of the biotechnology companySeptember 30, 2024 | marketbeat.com Remove Ads Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address ALDX Media Mentions By Week ALDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALDX News Sentiment▼1.070.82▲Average Medical News Sentiment ALDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALDX Articles This Week▼52▲ALDX Articles Average Week Remove Ads Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies WVE News Today ANIP News Today DYN News Today INDV News Today AMPH News Today LQDA News Today ETNB News Today EVO News Today SPRY News Today ARDX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALDX) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALDX Stock Free ALDX Stock Alerts